Immuneering Corporation (IMRX)
NASDAQ: IMRX
· Real-Time Price · USD
3.52
0.33 (10.34%)
At close: Jun 27, 2025, 3:59 PM
3.49
-0.99%
After-hours: Jun 27, 2025, 05:57 PM EDT
10.34% (1D)
| Bid | 3.47 |
| Market Cap | 126.85M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -61.77M |
| EPS (ttm) | -1.97 |
| PE Ratio (ttm) | -1.79 |
| Forward PE | -1.93 |
| Analyst | Buy |
| Ask | 3.5 |
| Volume | 2,673,316 |
| Avg. Volume (20D) | 994,316 |
| Open | 3.22 |
| Previous Close | 3.19 |
| Day's Range | 3.14 - 3.87 |
| 52-Week Range | 1.00 - 3.87 |
| Beta | 0.00 |
About IMRX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol IMRX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for IMRX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 week ago
-23.21%
Immuneering shares are trading lower. The company ...
Unlock content with
Pro Subscription
1 week ago
+24.74%
Immuneering shares are trading higher after the company announced it will provide updates from its Phase 2a clinical trial of IMM-1-104 in first-line pancreatic cancer patients.
